keyword
MENU ▼
Read by QxMD icon Read
search

Ventana

keyword
https://www.readbyqxmd.com/read/29156778/worse-disease-free-tumor-specific-and-overall-survival-in-surgically-resected-lung-adenocarcinoma-patients-with-alk-rearrangement
#1
Qiongqiong Gao, Pupu Li, Xiangli Jiang, Zhongli Zhan, Qingna Yan, Bo Zhang, Chun Huang
Introduction: This study determined the prevalence of anaplastic lymphoma kinase (ALK) rearrangement, and identified the associations of ALK rearrangement with clinicopathologic characteristics and treatment outcomes in patients with surgically-resected stage I-III lung adenocarcinoma. Methods: A total of 534 surgically-resected lung adenocarcinoma patients were studied. The prevalence of ALK protein over-expression was determined by a fully-automated immunochemistry assay (with mouse monoclonal Ventana D5F3 antibody), and the associations of ALK rearrangement with clinicopathologic characteristics and treatment outcomes were analyzed...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29119407/pd-l1-testing-in-guiding-patient-selection-for-pd-1-pd-l1-inhibitor-therapy-in-lung-cancer
#2
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz
Immunotherapy with programmed death 1 (PD-1)- and programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 and PD-L1 are immune checkpoint proteins whose binding ultimately result in T cell exhaustion and self-tolerance. Blocking this pathway 'releases the brakes' on the immune system and allows for attack of tumor cells that express PD-L1. The clinical trials that led to the US Food and Drug Administration (FDA) approval of these agents used different immunohistochemical (IHC) platforms with various PD-L1 antibodies to assess for PD-L1 expression on either tumor cells or tumor-infiltrating immune cells...
November 8, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/29105302/pd-l1-expression-associated-with-worse-survival-outcome-in-malignant-pleural-mesothelioma
#3
Bella Hai Nguyen, Renn Montgomery, Mitali Fadia, Jiali Wang, Sayed Ali
AIM: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has been studied as a prognostic biomarker in a number of tumors given its central role in antitumoral immune response evasion. Four previously published analyses found PD-L1 positivity to be an adverse survival prognostic factor in MPM. This study aims to further investigate the relationship between PD-L1 expression in mesothelioma tissues and survival outcome...
November 3, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29084031/companion-and-complementary-diagnostics-focus-on-pd-l1-expression-assays-for-pd-1-pd-l1-checkpoint-inhibitors-in-nsclc
#4
Maria Hersom, Jan Trøst Jørgensen
Over the last couple of decades, molecular diagnostics have played an increasing role in drug development. Especially within oncology, more and more drugs are being developed together with a predictive biomarker assay using the drug-diagnostic co-development model. Not only do these assays support the development process but also the use of the drugs after regulatory approval as an important treatment decision tool. When these predictive biomarker assays are linked to a specific drug, they are called companion diagnostics...
October 27, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29053400/programmed-death-ligand-1-immunohistochemistry-testing-a-review-of-analytical-assays-and-clinical-implementation-in-non-small-cell-lung-cancer
#5
Reinhard Büttner, John R Gosney, Birgit Guldhammer Skov, Julien Adam, Noriko Motoi, Kenneth J Bloom, Manfred Dietel, John W Longshore, Fernando López-Ríos, Frédérique Penault-Llorca, Giuseppe Viale, Andrew C Wotherspoon, Keith M Kerr, Ming-Sound Tsao
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non-small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing. Nivolumab and atezolizumab are approved without PD-L1 testing, though US Food and Drug Administration-cleared complementary PD-L1 tests are available for both. PD-L1 IHC assays used to assess PD-L1 expression in patients treated with programmed death-1/PD-L1 inhibitors in clinical trials include PD-L1 IHC 28-8 pharmDx (28-8), PD-L1 IHC 22C3 pharmDx (22C3), Ventana PD-L1 SP142 (SP142), and Ventana PD-L1 SP263 (SP263)...
October 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28969070/immunohistochemical-assays-incorporating-sp142-and-22c3-monoclonal-antibodies-for-detection-of-pd-l1-expression-in-nsclc-patients-with-known-status-of-egfr-and-alk-genes
#6
Paweł Krawczyk, Bożena Jarosz, Tomasz Kucharczyk, Anna Grenda, Katarzyna Reszka, Juliusz Pankowski, Kamila Wojas-Krawczyk, Marcin Nicoś, Justyna Szumiło, Tomasz Trojanowski, Janusz Milanowski
Different immunohistochemical (IHC) assays were approved for PD-L1 expression examination on tumor cells in qualification to immune-checkpoint inhibitors therapy in NSCLC patients. These assays have some similarities, but also very serious differences. We assessed 2 IHC tests for PD-L1 expression evaluation in NSCLC tumors with different pathological diagnoses and genetic abnormalities. We enrolled 48 NSCLC patients (median age: 65 years) with known status of EGFR and ALK genes. We compared the effectiveness of PD-L1 expression examination of two IHC assays with 22C3 (Dako) and SP142 antibodies (Ventana)...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28959173/pd-l1-expression-in-squamous-cell-carcinoma-and-adenocarcinoma-of-the-lung
#7
Urska Janzic, Izidor Kern, Andrej Janzic, Luka Cavka, Tanja Cufer
BACKGROUND: With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients. PATIENTS AND METHODS: We obtained 54 surgically resected tumor specimens and assessed PD-L1 expression by immunohistochemistry after staining them with antibody SP142 (Ventana, USA)...
September 2017: Radiology and Oncology
https://www.readbyqxmd.com/read/28932542/the-value-of-cell-block-based-on-fine-needle-aspiration-for-lung-cancer-diagnosis
#8
Zhengwei Dong, Hui Li, Jun Zhou, Wei Zhang, Chunyan Wu
BACKGROUND: Computed tomography (CT)-guided percutaneous lung fine needle aspiration (FNA) is a convenient method to obtain samples from pulmonary lesions. FNA has a lower rate of complications than the use of a core needle biopsy, but is more difficult for the diagnosis of cytological samples. We use cell block (CB) and immunocytochemistry (ICC) to improve the accuracy of cytological diagnoses based on CT-guided percutaneous lung FNA. METHODS: We collected 526 cytological samples obtained using CT-guided percutaneous lung FNA at Shanghai Pulmonary Hospital from May 2015 to October 2015...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28887531/homogeneity-and-high-concordance-of-alk-translocation-in-primary-lung-adenocarcinoma-and-paired-lymph-node-metastasis
#9
Wei Ma, Lei Guo, Ling Shan, Xiuyun Liu, Ning Lyu, Jianming Ying
Translocation of anaplastic lymphoma kinase (ALK) gene is an important determinator for the response to ALK tyrosine kinase inhibitor (TKI) in non-small-cell lung cancer (NSCLC) patients. The existence of genetic heterogeneity will affect the results of molecular testing, especially in biopsy samples from primary or metastatic sites of patients with advanced stage NSCLC. We intended to explore the heterogeneity of ALK gene translocation in excision specimens and to examine the existence of discordance of ALK status between primary tumours and corresponding lymph node metastases...
September 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28843709/pd-l1-in-breast-cancer-comparative-analysis-of-three-different-antibodies
#10
Tejashree Karnik, Bruce F Kimler, Fang Fan, Ossama Tawfik
The Programmed cell death-1 and its ligand-1 (PD-L1) interaction serve as a regulatory check against excessive immune response to antigen and autoimmunity. We compared the performance of three different PD-L1 antibodies (Ventana SP263, Dako 22C3 and BioCare RbMCAL10 antibodies) in 136 invasive ductal carcinoma specimens including 43 primary, 48 locally metastatic and 46 distantly metastatic disease. PD-L1 expression was correlated with clinicopathologic parameters including tumor size, grade, lymphovascular invasion, estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki67, molecular type, TN status...
August 23, 2017: Human Pathology
https://www.readbyqxmd.com/read/28818609/multicenter-comparison-of-22c3-pharmdx-agilent-and-sp263-ventana-assays-to-test-pd-l1-expression-for-nsclc-patients-to-be-treated-with-immune-checkpoint-inhibitors
#11
Antonio Marchetti, Massimo Barberis, Renato Franco, Graziano De Luca, Maria Vittoria Pace, Stefania Staibano, Marco Volante, Fiamma Buttitta, Elena Guerini-Rocco, Luisella Righi, Tommaso D'antuono, Giorgio V Scagliotti, Carmine Pinto, Gaetano De Rosa, Mauro Papotti
INTRODUCTION: Among the several agents targeting the programmed cell death 1 (PD-1) pathway, pembrolizumab is currently the only one approved for the treatment of patients with NSCLC in association with a companion diagnostic assay, the anti-PD-L1 immunohistochemical (IHC) 22C3 PharmDx (Agilent Technologies, Santa Clara, CA) using the Dako Autostainer (Dako, Carpinteria, CA). However, the Dako platform is not present in each pathology department, and this technical limitation is a major problem for the diffusion of the PD-L1 IHC predictive test for pembrolizumab...
November 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28797130/use-of-the-22c3-anti-pd-l1-antibody-to-determine-pd-l1-expression-in-multiple-automated-immunohistochemistry-platforms
#12
Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman
BACKGROUND: For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Optimised protocols are urgently needed for use of the 22C3 antibody concentrate to test PD-L1 expression on more widely available IHC autostainers. METHODS: We evaluated PD-L1 expression using the 22C3 antibody concentrate in the three main commercially available autostainers Dako ASL48, BenchMark ULTRA (Ventana Medical Systems, Inc...
2017: PloS One
https://www.readbyqxmd.com/read/28780052/validation-of-whole-slide-imaging-in-the-primary-diagnosis-of-liver-biopsies-in-a-university-hospital
#13
Adela Saco, Alba Diaz, Monica Hernandez, Daniel Martinez, Carla Montironi, Paola Castillo, Natalia Rakislova, Marta Del Pino, Antonio Martinez, Jaume Ordi
BACKGROUND: Experience in the use of whole slide imaging (WSI) for primary diagnosis is limited and there are no comprehensive reports evaluating this technology in liver biopsy specimens. AIMS: To determine the accuracy of interpretation of WSI compared with conventional light microscopy (CLM) in the diagnosis of needle liver biopsies. METHODS: Two experienced liver pathologists blindly analyzed 176 consecutive biopsies from the Pathology Department at the Hospital Clinic of Barcelona...
November 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28767565/small-intestine-follicular-dendritic-cell-sarcoma-with-liver-metastasis-a-case-report
#14
Yun-Chen Chang, Ivy Yenwen Chau, Yi-Chen Yeh, Gar-Yang Chau
RATIONALE: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasia composed of spindle or oval cells with follicular dendritic cell differentiation, usually occurring in lymphoid tissue. In this report, we present a case of FDCS of the small intestine with liver metastasis. PATIENT CONCERNS: A 19-year-old female presented with recent onset of left upper abdominal pain. Abdominal computed tomography scan showed a large tumor mass in the liver lateral segment with compression to the pancreas upper part, and a smaller mass in the terminal ileum, respectively...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28742247/ventana-immunohistochemistry-assay-for-anaplastic-lymphoma-kinase-gene-rearrangement-detection-in-patients-with-non-small-cell-lung-cancer-a-meta-analysis
#15
Wang Zhiwei, Jiang Yuan, Yao Yihui, Hou Xin, Chen Jingtao, Shi Lei, Duan Yongjian
BACKGROUND: The aim of this study was to evaluate the diagnostic value of Ventana immunohistochemistry (IHC) assay for anaplastic lymphoma kinase (ALK) gene rearrangement screening in patients with non-small cell lung cancer (NSCLC). METHODS: Open published studies that reported the diagnostic performance of Ventana IHC assay for ALK gene rearrangement detection in NSCLC patients were extracted from PubMed, Embase, Google scholar, Wanfang, and China National Knowledge Infrastructure...
September 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28677240/application-of-automated-image-analysis-reduces-the-workload-of-manual-screening-of-sentinel-lymph-node-biopsies-in-breast-cancer
#16
Henrik Holten-Rossing, Maj-Lis Møller Talman, Anne Marie Bak Jylling, Anne-Vibeke Laenkholm, Martin Kristensson, Ben Vainer
AIMS: Breast cancer is one of the most common cancer diseases in women, with >1.67 million cases being diagnosed worldwide each year. In breast cancer, the sentinel lymph node (SLN) pinpoints the first lymph node(s) into which the tumour spreads, and it is usually located in the ipsilateral axilla. In patients with no clinical signs of metastatic disease in the axilla, an SLN biopsy (SLNB) is performed. Assessment of metastases in the SLNB, when using a conventional microscope, is performed by manually observing a metastasis and measuring its size and/or counting the number of tumour cells...
July 5, 2017: Histopathology
https://www.readbyqxmd.com/read/28667193/pd-l1-protein-expression-in-tumour-cells-and-immune-cells-in-mismatch-repair-protein-deficient-and-proficient-colorectal-cancer-the-foundation-study-using-the-sp142-antibody-and-whole-section-immunohistochemistry
#17
Tony El Jabbour, Jeffrey S Ross, Christine E Sheehan, Kajsa E Affolter, Katherine B Geiersbach, Ann Boguniewicz, Sanaz Ainechi, Mary P Bronner, David M Jones, Hwajeong Lee
AIMS: Routine application of PD-L1 immunohistochemistry (IHC) in colorectal cancer (CRC) is limited due to lack of standardized scoring criteria, antibody clones, and intratumoral staining heterogeneity. We assessed PD-L1 protein expression on full face CRC tissue sections and applied two algorithms based on the published clinical trials that support the recent FDA approval for immune checkpoint inhibitors (ICPI) therapy in non-small cell lung cancer (NSCLC). METHODS: PD-L1/CD274 IHC (Roche/Ventana, clone SP142) was performed on representative tumour blocks from 52 mismatch repair-deficient (MMR-D) and 52 MMR-proficient (MMR-P) CRCs...
June 30, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28638113/clinical-significance-and-next-generation-sequencing-of-chinese-pulmonary-sarcomatoid-carcinoma
#18
Xin Li, Dan Wang, Qingchun Zhao, Dian Ren, Fan Ren, Gang Chen, Hongyu Liu, Jun Chen
Pulmonary Sarcomatoid Carcinoma (PSC) constitutes a heterogeneous group of non-small-cell lung carcinomas (NSCLCs) with a poor prognosis. In this study, a group of 7 patients with PSC was studied. Microscope analysis of all 7 cases revealed a pleomorphic carcinoma subtype. Moreover, 5 cases (71.4%) were composed entirely of malignant sarcomatoid-like elements, and 2 cases (28.6%) were composed of malignant sarcomatoid-like elements and at least 10% adenocarcinoma-like elements. Immunohistochemically, the PSC components of all 7 cases were positive for vimentin and cytokeratins, including cytokeratin (CK) and cytokeratin 7 (CK7)...
June 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28631631/ki-67-evaluation-in-breast-cancer-the-daily-diagnostic-practice
#19
Lukasz Fulawka, Agnieszka Halon
CONTEXT: Breast cancer is the most common malignancy in females. It is routinely classified according to the WHO histological typing. However, there is also a molecular classification of breast cancer which is routinely substituted with surrogate subtypes based on expression of estrogen, progesterone, and human epidermal growth factor receptor 2 receptors and proliferation index (PI). PI is defined as the percentage of Ki-67-positive cells among overall cell population. The method commonly applied by pathologists to determine PI is visual scoring of the sample...
April 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28625320/expression-of-jagged1-notch3-signaling-pathway-and-their-relationship-with-the-tumor-angiogenesis-in-tnbc
#20
Siliang Xue, Lang He, Xiao Zhang, Jin Zhou, Fanghua Li, Xiaoshan Wang
BACKGROUND AND AIMS: Jagged1/Notch3 signaling pathway plays a key role in angiogenesis of breast cancer, but little is known in TNBC. This study was designed to investigate the expression of Jagged1/Notch3 mRNA and protein in TNBC, analyze their correlations with clinicopathological characteristics and prognosis. Moreover, the interrelationship among Jagged1/Notch3 and VEGF was initially evaluated. METHODS: Jagged1/Notch3 mRNA and protein expression levels were determined by Q-RT-PCR and Western blotting...
February 2017: Archives of Medical Research
keyword
keyword
29584
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"